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Background. Whereas human immunodeficiency virus (HIV) subtype B–infected individuals generally progress
to AIDS within 8–10 years, limited data exist for other clades, especially from Africa. We investigated rates of HIV
disease progression of clade C–infected South African women.
Methods. Prospective seroincidence cohorts in KwaZulu-Natal were assessed for acute HIV infection monthly
(n = 245) or every 3 months (n = 594) for up to 4 years. Rapid disease progression was defined as CD4 decline to
<350 cells/µL by 2 years postinfection. Serial clinical and laboratory assessments were compared using survival
analysis and logistic regression models.
Results. Sixty-two women were identified at a median of 42 days postinfection (interquartile range, 34–59), con-
tributing 282 person-years of follow-up. Mean CD4 count dropped by 39.6% at 3 months and 46.7% at 6 months
postinfection in women with preinfection measurements. CD4 decline to <350 cells/µL occurred in 31%, 44%, and
55% of women at 1, 2, and 3 years postinfection, respectively, and to <500 cells/µL in 69%, 79%, and 81% at equiv-
alent timepoints. Predictors of rapid progression were CD4 count at 3 months postinfection (hazard ratio [HR], 2.07;
95% confidence interval [CI], 1.31–3.28; P = .002), setpoint viral load (HR, 3.82; 95% CI, 1.51–9.67; P = .005), and
hepatitis B coinfection (HR, 4.54; 95% CI, 1.31–15.69; P = .017). Conversely, presence of any of HLAB*1302, B*27,
B*57, B*5801, or B*8101 alleles predicted non–rapid progression (HR, 0.19; 95% CI, .05–.74; P = .016).
Conclusions. Nearly half of subtype C–infected women progressed to a CD4 count <350 cells/µL within 2 years
of infection. Implementing 2013 World Health Organization treatment guidelines (CD4 count <500 cells/µL) would
require most individuals to start antiretroviral therapy within 1 year of HIV infection.
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Human immunodeficiency virus (HIV) disease pro-
gression is highly variable between individuals and pop-
ulations and is determined by genetic, immunologic,
virologic, and environmental factors [1–3]. CD4+
T-cell decline has been recognized as one of the
major markers of the rate of HIV disease progression.
Once CD4 counts drop below 200 cells/µL, the risk of
opportunistic infections and death increases dramati-
cally. In addition to CD4 decline, disease progres-
sion can be defined by time to antiretroviral therapy
(ART) initiation, diagnosis of AIDS-defining illnesses,
or death. Whereas the majority of HIV-infected indi-
viduals (70%–80%) fall into an intermediate category,
rapid progression and long-term nonprogression repre-
sent extreme phenotypes with respect to CD4 decline
[4]. In addition, the infecting subtype can have a signifi-
cant impact on the rate of CD4 decline [5, 6]. This has
been best defined for clades A and D in East Africa,
Received 26 April 2014; accepted 2 July 2014; electronically published 17 July
2014.
Correspondence: Koleka Mlisana, MBChB, MMed Path (Microbiology), Depart-
ment of Medical Microbiology, Level 4 Laboratory Building, National Health Labo-
ratory Services and University of KwaZulu-Natal, 800 Bellair Road, Mayville, Durban
4058, South Africa (mlisanak@ukzn.ac.za).
Clinical Infectious Diseases® 2014;59(9):1322–31
© The Author 2014. Published by Oxford University Press on behalf of the Infectious
Diseases Society of America. All rights reserved. For Permissions, please e-mail:
journals.permissions@oup.com.
DOI: 10.1093/cid/ciu573
1322 • CID 2014:59 (1 November) • HIV/AIDS
where studies demonstrated a shorter median time to AIDS
in subtype D–infected individuals than in subtype A–
infected individuals [7–9]. Studies from sub-Saharan Africa
suggest faster disease progression in subtype C–infected indi-
viduals [10, 11], despite observations that subtype C may repli-
cate less efficiently than subtype B [12].
A major immunologic predictor of progression is the level of
host immune activation, which predicts rates of CD4 decline
more accurately than plasma viral load (VL) [13]. African pop-
ulations have reportedly higher levels of immune activation
than US populations, possibly linked to a higher burden of
comorbidities and micronutrient deficiencies [14, 15]. Indirect
immune activation caused by microbial translocation and loss
of gut-associated CD4 cells has also been demonstrated in
HIV rapid progressors [16]. Another major host predictor of
disease progression is the human leukocyte antigen (HLA)
background. HLA-B35, B8, B45, and B53 have been associated
with rapid progression, whereas HLA-B57 and B27 are more
common in slow progressors [11, 17–19].
Results from mostly subtype B–infected cohorts suggest that
rapid progression is uncommon, with only about 5% of individ-
uals progressing from acute HIV infection to AIDS within 3
years [20, 21]. However, there are limited data on disease pro-
gression in other subtypes, especially from prospective African
cohorts infected with subtype C. This study describes HIV type
1 (HIV-1) disease progression in South African women and
identifies host and viral factors associated with progression.
METHODS
Study Population
Between August 2004 and May 2005, a cohort of HIV-uninfected
women at high risk of HIV acquisition was enrolled into the Cen-
tre for the AIDS Programme of Research in South Africa (CAP-
RISA) 002 Acute Infection Study, recruited at 2 sites within the
province of KwaZulu-Natal in South Africa—an urban site in
Durban and a rural site in Vulindlela. The aim of the study was
to describe immunologic, virologic, and clinical characteristics of
HIV-1 subtype C acute infection and investigate the natural his-
tory of HIV-1 subtype C infection [22].Women aged ≥18 years
who self-reported as sex workers or having >3 sexual partners
within the last 3 months were screened. Those testing HIV neg-
ative were offered enrollment and followed for up to 4 years,
with monthly testing to identify acute HIV infections [23]. In
addition, women were also recruited from a rural family plan-
ning and sexually transmitted infection (STI) clinics in Durban
[24] with quarterly HIV testing and follow-up. Written in-
formed consent was obtained from all participants, and ethical
approval for the study was granted by the University of KwaZu-
lu-Natal (E013/04), University of Cape Town (025/2004), and
University of the Witwatersrand (M040202).
HIV Testing and Time of Infection
HIV diagnosis was based on antibody and/or nucleic acid
detection. Two point-of-care antibody tests were used, the
third-generation Determine (Abbott Laboratories, Abbott Park,
Illinois) and Capillus (Trinity Biotech, Jamestown, New York).
An HIV enzyme-linked immunosorbent assay was performed
to confirm HIV diagnosis using the HIV enzyme immunoassay
BEP 2000 (Dade Behring, Marburg, Germany). HIV reverse
transcription polymerase chain reaction (RT-PCR) testing was
performed at every testing with antibody-negative results.
COBAS Amplicor version 1.5 RT-PCR testing (Roche Diagnos-
tics, Rotkreuz, Switzerland) was performed using a pooling
strategy of 24 samples per pool [25, 26]. Time of infection
was estimated as the midpoint between last antibody-negative
and first antibody-positive test or 14 days before a positive
RT-PCR result for those diagnosed preseroconversion.
Once HIV diagnosis was confirmed, women were enrolled into
the acute HIV infection cohort. The visit structure was divided into
3 phases: weekly to fortnightly visits up to 3 months postinfection
(acute infection), monthly visits from 3 to 12 months (early in-
fection), and quarterly visits thereafter (established infection)
until ART initiation. Samples for immunologic, virologic, and
clinical parameters were collected, and VL and CD4 counts
(FACSCalibur Flow Cytometer, BD Biosciences, San Jose,
California) were measured at each visit. Screening for STIs
with multiplex PCR testing and Gram stain for bacterial vaginosis
were performed at enrollment and every 6 months thereafter [27].
Womenwith positive results were recalled for treatment or referred
to the nearest clinic. Any other STIs were treated syndromically
on presentation according to South African National Guidelines.
High-resolution HLA typing was performed on all partici-
pants. DNA was extracted from either peripheral blood mono-
nuclear cells or granulocytes using the Pel-Freez DNA Isolation
kit. HLA-A, -B, and -C typing was performed by sequencing of
exons 2, 3, and 4 using Atria AlleleSeqr kits (Abbott), and data
were analyzed using Assign-SBT 3.5 (Conexio Genomics). Any
ambiguities resulting from either polymorphisms outside the
sequenced exons or identical heterozygote combinations were
resolved using sequence-specific primers.
Statistical Analysis
Basic descriptive statistics were used to summarize frequencies
and timing of the first occurrences of clinical signs and symp-
toms. Linear mixed models were used to estimate the CD4
slope within 12 months of HIV infection. Kaplan–Meier anal-
yses were carried out using estimated time of infection to
endpoints of CD4 counts of <200, <350, and <500 cells/µL.
Stratified analyses using 3- and 6-month postinfection VL (<5
and ≥5 log copies/mL) were also performed. Whereas rapid
disease progression is currently defined as ≥2 CD4 measure-
ments <350 cells/µL within 3 years of seroconversion [28], we
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conservatively defined it as 2 consecutive CD4 counts <350 cells/
µL between 6 months (to exclude seroconversion decline) and 24
months postinfection. Non–rapid progressors (NRPs) were those
maintaining a CD4 count >350 cells/µL beyond 24months. Base-
line differences between rapid progressors (RPs) and NRPs were
assessed by Wilcoxon rank-sum and Fisher exact tests. Cox pro-
portional hazards regression modeling was used to assess predic-
tors of rapid progression. Participants who did not progress
rapidly were censored at their last follow-up visit or 24 months
postinfection, whichever came first. Predictors in the unadjusted
model with P values <.20, or deemed important, were included in
the adjusted model. Statistical analysis was performed using SAS
software, version 9.3 (SAS Institute Inc., Cary, North Carolina);
graphs were prepared using Graph Pad Prism 5.
RESULTS
Baseline Characteristics of the Cohort
Of the 245 HIV-negative women followed up monthly for
4 years, 35 (14.3%) acquired HIV. The 594 HIV-negative
women followed quarterly from seroincidence cohorts yielded
39 HIV seroconversions; 27 of these women consented to fur-
ther follow-up. HIV incidence rates were similar between co-
horts (6.5/100 person-years [95% confidence interval {CI},
4.6–8.9] for the N = 594 women and 7.2/100 person-years
[95% CI, 4.5–9.8] for the N = 245 women) [29], and the cohorts
had minimal influence on progression rates (hazard ratio [HR],
0.61 [95% CI, .29–1.32]; P = .209). Of the 62 HIV infections,
17 (27%) were diagnosed before seroconversion. The median
time from estimated date of infection to first HIV-positive
sample was 42 days (interquartile range [IQR], 34–59 days).
Demographic, behavioral, and clinical characteristics of these
women are summarized in Table 1. The median age at HIV in-
fection was 25 years (IQR, 21–33 years), and most women
(71.0%) were either married or had a stable partner. At enroll-
ment into the acute HIV infection cohort, STIs were common
(44.3%), and most women (91.9%) were seropositive for herpes
simplex virus type 2 (HSV-2). The overall mean CD4 count at
this first postseroconversion timepoint was 520 cells/µL. This
was significantly lower than the preinfection CD4 counts
Table 1. Demographic and Behavioral Characteristics of the Acute HIV Infection Cohort




Progressors (n = 35) P Value
Days postinfection at enrollmenta, median (IQR) 42 (34–59) 42 (30–59) 46 (34–60) .804
Age, y, median (IQR) 25 (21–33) 27 (23–36) 24 (21–33) .163
Urban 74.2% (46) 85.2% (23) 65.7% (23) .142
Completed high school 29.0% (18) 29.6% (8) 28.6% (10) 1.000
Marital status
Married or stable partner 71.0% (44) 59.3% (16) 80.0% (28) .240
Many partners 16.1% (10) 22.2% (6) 11.4% (4)
No partners 12.9% (8) 18.5% (5) 8.6% (3)
No. of sexual partners in last 3 mo prior to HIV infectiona
0–1 68.3% (41) 55.6% (15) 78.8% (26) .093
≥2 31.7% (19) 44.4% (12) 21.2% (7)
Commercial sex workers 32.3% (20) 33.3% (9) 31.4% (11) 1.000
Condom used at last sex act 56.5% (35) 59.3% (16) 54.3% (19) .798
Ever had anal sex 14.5% (9) 22.2% (6) 8.6% (3) .160
History of tuberculosis 8.1% (5) 3.7% (1) 11.4% (4) .376
BMIa, median (IQR) 26.6 (23.5–31.8) 26.8 (23.9–32.1) 26.4 (22.7–31.3) .287
CD4 counta, mean (SD) 520 (193.61) 413 (128.95) 603 (195.88) <.001
Log viral loada, median (SD) 4.62 (0.92) 4.96 (0.84) 4.36 (0.90) .009
Bacterial vaginosisa 73.3% (44/60) 66.7% (18/27) 78.8% (26/33) .382
Any STIa,b 44.3% (27/61) 40.7% (11/27) 47.1% (16/34) .796
HSV-2 Ab positivea 91.9% (57) 92.6% (25) 91.4% (32) 1.000
HBcAb positivea 50.0% (31) 59.3% (16) 42.9% (15) .306
Data are presented as % (No.) unless otherwise specified.
Abbreviations: Ab, antibody; BMI, body mass index; HBcAb, hepatitis B core antibody; HIV, human immunodeficiency virus; HSV-2, herpes simplex virus type 2;
IQR, interquartile range; SD, standard deviation; STI, sexually transmitted infection.
a Measured at enrollment into acute HIV infection cohort.
b Any sexually transmitted disease, defined as testing positive for Treponema pallidum, Trichomonas vaginalis, Neisseria gonorrhoeae, Chlamydia trachomatis,
Mycoplasma genitalium, or HSV-2 polymerase chain reaction.
1324 • CID 2014:59 (1 November) • HIV/AIDS
(mean CD4 count, 993 cells/µL available for 25 of 62 women;
P < .001). The CD4 counts differed significantly between RPs
and NRPs (413 vs 603 cells/µL; P < .001; Table 1) at first post-
seroconversion with a mean log VL of 4.62 log copies/mL
(SD = 0.92) and higher levels in RPs than NRPs (4.96 vs 4.36
log copies/mL; P = .009).
Prospective Analysis
A total of 282 person-years of ART-naive follow-up amongst
participants not yet initiated on ART were observed, including
a median of 33 CD4 count or VL measurements (range, 3–45)
per participant. In the first 2 years of HIV infection, the median
number of CD4 count measures for RP and NRP participants
was 19 (IQR, 16–20) and 19 (IQR, 18–20), respectively. At
the time of analysis, 17 of 62 women remained ART-naive
and were an estimated 6.4 years postinfection (IQR, 5.9–7.1
years) at their last follow-up visit. Of the remainder, 37 initiated
ART, 5 died (2 HIV-related deaths), 2 were lost to follow-up
(prior to ART initiation), and 1 declined study participation.
Almost one-third (30.6%) reached a CD4 count of <350 cells/
µL within 6–12 months of infection, 43.5% within 24 months,
and 54.8% within 36 months postinfection (Figure 1). Increas-
ing the treatment threshold to CD4 count <500 cells/µL, in
keeping with the 2013 consolidated World Health Organiza-
tion (WHO) guidelines [30], would have resulted in 69.4%
of women qualifying for treatment within 6–12 months post-
infection, 79.0% within 24 months, and 80.6% within 36
months.
Rapid progressors lost 11.5 CD4+ cells/µL per month in the
first year of infection, compared with NRPs who lost 6.1 CD4+
cells/µL (P = .019). For the 25 women with available preinfection
CD4 counts (mean, 993 cells/µL), this count dropped by 39.6%
(SD, 20.25%) at 3 months and 46.7% (SD, 22.04%) at 6 months
postinfection. Rapid progressors experienced a larger CD4 drop
during acute infection (48.2% vs 30.2% from preinfection to se-
roconversion; P = .023). There were no significant differences in
Figure 1. Superimposed Kaplan–Meier graphs of time to CD4 count <200, <350, and <500 cells/µL since estimated date of infection. Abbreviations: CI,
confidence interval; IR, incidence rate; PY, person-years.
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the preinfection CD4 counts between RPs and NRPs (mean CD4
count, 960 cells/µL and 1029 cells/µL, respectively; P = .649)
(Supplementary Figure 1). These data suggest that severe deple-
tion of CD4 T cells in early infection is highly predictive of
subsequent disease progression.
Plasma Viral Loads as a Predictor of Rapid Disease Progression
The mean of the first available VL in this cohort (including the
available preseroconversion RT-PCR results) was 4.83 log cop-
ies/mL (SD, 1.10), at a median of 31 days postinfection (IQR,
14–58 days), likely representing the decline following peak vire-
mia. Mean VL dropped to 4.26 (SD, 0.91) and 4.20 (SD, 0.95)
log copies/mL at 6 and 12 months, respectively, representing
setpoint viremia. Viral loads were significantly higher in RPs
than in NRPs, with a mean VL at 3 months postinfection of
4.86 log copies/mL (SD, 0.62) compared with 4.13 log copies/
mL (SD, 0.86; P < .001).
To further determine the impact of VL on disease progres-
sion, we compared CD4 decline in participants with high VL,
using a cutoff of 5 log copies/mL. Participants with higher VL
at 3 months postinfection were more likely to reach a CD4
count <350 cells/µL sooner (log-rank P < .001), compared
with women with lower VL. At 24 months postinfection, 77%
of those who had high VL at 3 months reached the endpoint,
compared with 35% of the lower VL group. The median time
to endpoint for those with high VL was 6.7 months from infec-
tion compared with 34.6 months with a low VL (Figure 2). Sim-
ilar results were obtained for VL at 6 months postinfection. The
data for a CD4 count endpoint of <500 cells/µL were even more
dramatic, with the probability of reaching the endpoint by 2
Figure 2. Kaplan–Meier graphs depicting time to CD4 <350 cells/μL and CD4 <500 cells/μL stratified by viral load at 3 and 6 months postinfection.
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years postinfection for those with high and low VL, reaching
0.93 and 0.75, respectively.
Timing of Clinical Conditions From Acute Infection
The timing of the first presentation of clinical events during the
acute phase and subsequent course of HIV infection is shown in
Figure 3. Almost all participants experienced lymphadenopathy
(98.4%), and many presented with upper respiratory tract infec-
tion (38.7%), vaginal discharge (87.1%), and genital ulcer dis-
ease (19.4%) during acute HIV infection. Whereas women
presented with fungal infection and nonspecific skin rashes
throughout the disease course, other infections such as shingles,
lower respiratory tract infections, and tuberculosis were diag-
nosed later during HIV infection. Aside from 2 participants
who died of HIV-related diseases (tuberculosis and cryptococ-
cal meningitis), there were no other AIDS-defining diagnoses in
the cohort. Of 41 participants, who became eligible and were
referred for ART during the study, 37 have so far initiated ART.
Predictors of Rapid HIV Disease Progression
In the unadjusted analysis, associations were noted between
rapid progression and not having a regular partner (HR, 3.03
[95% CI, 1.07–8.53]; P = .036), having ≥2 sexual partners in
the 3 months prior to infection (HR, 2.06 [95% CI, .96–4.41];
P = .063), and being enrolled at the urban site (HR, 2.47 [95%
CI, .85–7.14]; P = .096). CD4 count decline from pre–HIV in-
fection (HR, 1.56 [95% CI, 1.12–2.17 per 10% decrease];
P = .008) and incident hepatitis B infection during the first 6
months (HR, 8.98 [95% CI, 2.21–36.47]; P = .002) were also
predictive of rapid disease progression. Notably, in the 3 cases
of incident hepatitis B infection identified between HIV acqui-
sition and 6 months postinfection, all rapidly progressed to a
CD4 count <350 cells/µL. No associations were observed for
age, education, sex worker status, or clinical data including a
history of tuberculosis, body mass index, an abnormal full
blood count result, or STIs at enrollment into the acute HIV in-
fection cohort (Table 2).
Overall, the best independent predictors of CD4 decline and
rapid disease progression were CD4 count at 3 months (HR,
2.07 [95% CI, 1.31–3.28 per 100 cells/µL decrease]; P = .002),
VL during early infection (HR, 3.82 [95% CI, 1.51–9.67 per
1-log increase]; P = .005), and hepatitis B infection at the time
of HIV infection (HR, 4.54 [95% CI, 1.31–15.69]; P = .017).
Conversely, the best predictors of non–rapid progression were
any of the previously described protective HLA genotypes
(B*1302, B*27, B*57, B*5801, B*8101), with an HR of 0.19
(95% CI, .05–.74; P = .016).
DISCUSSION
The rate of HIV disease progression is highly variable, with im-
portant implications for both clinical disease management and
program planning. Previous studies have estimated that rapid
HIV progression is relatively uncommon, using definitions of
CD4 decline within 3 years [31]. Here, we show that nearly
half of the clade C–infected women met our conservative defi-
nition of rapid disease progression (CD4 decline to <350 cells/
Figure 3. Time to first episode of clinical conditions from acute human immunodeficiency virus infection experienced by study participants. Circles
represent participants and when they experienced the first episode of the corresponding clinical condition.
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Demographic and behavioral characteristics
Age (per 5 y increase) 1.03 (.85–1.24) .761 0.82 (.55–1.21) .317
Completed high school No 19/44 1.0 (Ref)
Yes 8/18 1.09 (.48–2.49) .840
Marital status Married or stable
partner
16/44 1.0 (Ref) 1.0 (Ref)
Many partners 6/10 2.05 (.80–5.25) .135 0.19 (.03–1.42) .105
No partner 5/8 3.03 (1.07–8.53) .036 0.22 (.03–1.64) .139
Site Rural 4/16 1.0 (Ref) 1.0 (Ref)
Urban 23/46 2.47 (.85–7.14) .096 2.09 (.41–10.63) .374
No. of sexual partners in last 3 m 0–1 15/41 1.0 (Ref) 1.0 (Ref)
≥2 12/19 2.06 (.96–4.41) .063 4.21 (.70–25.35) .117
Condom at last sex act Yes 16/35 1.0 (Ref)
No 11/27 0.84 (.39–1.82) .666
Sex worker No 18/42 1.0 (Ref)
Yes 9/20 1.07 (.48–2.39) .864
Ever had anal sex No 21/53 1.0 (Ref) 1.0 (Ref)
Yes 6/9 1.93 (.78–4.79) .157 0.91 (.23–3.57) .894
Routine clinical and laboratory assessment
Personal or family history of
hypertension or diabetes
No 15/34 1.0 (Ref)
Yes 12/28 0.93 (.44–1.99) .858
Creatinine count at 3 mo postinfection 0.96 (.91–1.01) .087 0.97 (.91–1.04) .369
History of tuberculosis No 26/57 1.0 (Ref)
Yes 1/5 0.40 (.05–2.97) .373
BMI at enrollment, kg/m2 0.99 (.94–1.05) .823
Hemoglobin at 3 mo, g/dL ≥12 15/31 1.0 (Ref)
<12 12/31 0.72 (.33–1.53) .387
Neutrophil count at 3 mo, ×109/L ≥2.5 13/29 1.0 (Ref)
<2.5 14/32 1.03 (.49–2.20) .932
Platelets at 3 mo, ×109/L 1.00 (.99–1.00) .692
Elevated liver function tests at 3 mob No 22/51 1.0 (Ref)
Yes 5/11 1.00 (.38–2.65) .993
CD4+ count decline from baseline
(by 10% decrease)
1.56 (1.12–2.17) .008
CD4+ count at 3 mo (by 100 cells/µL
decrease)
1.98 (1.43–2.74) <.001 2.07 (1.31–3.28) .002
Log viral load at 3 mo
(by 1 log increase)
2.77 (1.63–4.70) <.001 3.82 (1.51–9.67) .005
Any STIc at enrollment No 16/34 1.0 (Ref)
Yes 11/27 0.58 (.38–1.78) .621
HBcAb status at enrollment Negative 11/31 1.0 (Ref) 1.0 (Ref)
Positive 16/31 1.52 (.70–3.27) .287 4.54 (1.31–15.69) .017
HBcAb status at 6 mo Remained negative 7/24 1.0 (Ref)
Baseline positive 14/27 2.10 (.85–5.22) .109
New infection 3/3 8.98 (2.21–36.47) .002
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µL within 2 years of HIV-1 infection). Similar findings have
been reported from Argentina where 26% of untreated acute
HIV infections showed clinical or immunological progression
within 12 months of infection [32]. The high proportion of
women experiencing rapid disease progression suggests that
this may be the dominant phenotype in the natural history of
HIV-1 disease in our setting. This finding supports the argu-
ment of starting ART early, especially in settings where the
risk of coinfections such as tuberculosis is high. The 2013
WHO guidelines suggest starting ART at a CD4 count of
<500 cells/µL [30]. Here, we showed that nearly three-quarters
of HIV-infected individuals will reach this threshold within 1
year of infection.
Preinfection CD4 counts in this population were similar to
those in developed countries, with no association between prein-
fection CD4 counts and disease progression rate. A striking find-
ing in this study is the magnitude of CD4 cell depletion during
acute HIV infection, with nearly half of preinfection CD4 cells
lost within the first 6 months of HIV infection. We observed
very little CD4 cell rebound after acute infection, in contrast to
the modest and transient loss described inmost published studies.
The rate of CD4 cell loss in the rapid progressors is higher than
that observed in other HIV-1 subtype C–infected cohorts [5].
We have previously shown in this cohort that the magnitude
or breadth of T-cell recognition across the expressed genome at
3 months had no association with viral setpoint at 12 months
[33] and that recognition of more conserved epitopes in Gag
tended to associate with slow disease progression in the first
year of infection. This was in parallel with the accumulation
of less differentiated Gag-specific CD8+ T memory cells by 6–
9 months postinfection in individuals with lower viral setpoints
[34]. It appeared that the higher setpoint induced a greater level
of immune activation, which resulted in high T-cell turnover
being directly proportional to the level of viremia [13, 35].
This study confirms the direct association of high VL with
rapid CD4+ cell loss, which, in turn, is related to levels of
T-cell activation [36].Collectively, these data suggest that recog-
nition of class I HLA–restricted variant epitopes and the late
stage of CD8+ memory differentiation are concentrated in
women with rapid disease progression. We have previously
shown that the frequency of conserved HLA-B restricted epi-
topes is more abundant in non–rapid progressors [37].
The long-term follow-up of this cohort enabled us to describe
the trajectory of clinical signs and symptoms occurring in these
women. STIs (genital ulcers and discharge) were common dur-
ing early infection, whereas other infections such as varicella
and tuberculosis occurred later. This is likely because the former
are co-transmitted, or are the result of reduced mucosal barrier
function as a result of CD4 loss, whereas the latter require more
advanced immunodeficiency. Although this cohort showed
rapid immunologic progression, there was little evidence of se-
vere clinical disease or early AIDS-defining illnesses within the
first 3 years of infection [32], compared with what has been ob-
served in other cohorts. The most likely reason for this was the
close follow-up of participants and prompt ART initiation prior
to onset of AIDS.
A limitation of this acute HIV-infected cohort is the relatively
small sample size, albeit comparable to similar cohorts, and our
findings may therefore not be generalizable outside our setting.
Because this was a female cohort, caution would need to be ex-
ercised when extrapolating these results on disease progression
to the male population.
The rapid progression observed in this cohort provides
















Protective HLA-B typesd No 24/47 1.0 (Ref) 1.0 (Ref)
Yes 3/15 0.30 (.09–.99) .048 0.19 (.05–.74) .016
Harmful HLA-B typesd No 18/43 1.0 (Ref)
Yes 9/19 1.04 (.47–2.32) .922
Abbreviations: BMI, body mass index; CI, confidence interval; HBcAb, hepatitis B core antibody; HLA, human leukocyte antigen; HR, hazard ratio; Ref, reference;
STI, sexually transmitted infection.
a Due to missing data, the adjusted analysis was performed on a total of 55 participants, with 26 events of rapid disease progression.
b Elevated liver function tests defined as having alanine aminotransferase level >35 IU/L and/or aspartate aminotransferase level >35 IU/L.
c Any sexually transmitted disease, defined as testing positive for Treponema pallidum, Trichomonas vaginalis, Neisseria gonorrhoeae, Chlamydia trachomatis,
Mycoplasma genitalium, or herpes simplex virus type 2 polymerase chain reaction.
d Protective HLA-B types are B*1302, B*27, B*57, B*5801, B*8101. Harmful HLA-B types are B*1801, B*35, B*5802.
HIV/AIDS • CID 2014:59 (1 November) • 1329
Although this may present economic and operational challenges,
the fact that half of individuals need ART in the first year of HIV
infection provides compelling data for continued treatment roll-
out. Long-term ART use will bring challenges of adherence and
potential development of drug resistance, and require more
health system strengthening to manage HIV as a chronic illness.
Despite the challenges, this study suggests that earlier treatment
initiation carries many benefits, including the potential for major
impact on individual health by increasing survival and on public
health by preventing transmission. The concept of “test and
treat” might even be more pertinent in KwaZulu-Natal in
South Africa, where we show that rapid disease progression in
women is disturbingly common. Given the newWHO guidelines
of ART initiation at a CD4 count of ≤500 cells/µL, more effort
should be placed into diagnosing acute HIV infection to ensure
that the large proportion of women requiring treatment within
the first year of infection are not missed.
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